.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Precision oncology is evolving rapidly as researchers explore the deep connections between genomic biomarkers. The integration of HRD and Replication Stress (RS) has emerged as a vital strategy for improving cancer treatment in India and globally. These two hallmarks of genomic instability often occur together and offer unique opportunities for therapeutic targeting.
Recent pan-cancer analyses highlight that combining poly ADP-ribose polymerase inhibitors (PARPi) with immune checkpoint blockade (ICB) increases efficacy significantly. Furthermore, targeting the replication stress response can effectively overcome resistance often seen in mono-therapies. This synergistic approach aims to maximize tumor cell death while maintaining manageable toxicity levels.
Consequently, experts are developing a unified therapeutic axis that focuses on both HRD and RS pathways simultaneously. In addition, novel assays are now helping to identify patients who will benefit most from these next-generation strategies. Therefore, integrating functional assessments with immune contexture will likely become the future standard for guiding precision oncology.
They are interconnected hallmarks of genomic instability. HRD increases susceptibility to DNA damage, while replication stress involves the stalling of replication forks. Together, they create a functional axis for targeted drugs.
Combining PARP inhibitors with replication stress inhibitors or immunotherapy can improve treatment efficacy. This approach often overcomes the resistance found in traditional monotherapy regimens.
Disclaimer: This content is for informational and educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
1. Ozmen TY et al. Integrating homologous recombination deficiency and replication stress: converging strategies unlocking new frontiers in precision oncology. Expert Rev Clin Pharmacol. 2026 Apr 26. doi: 10.1080/17512433.2026.2665447. PMID: 42035488.
2. Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science. 2017 Mar 17;355(6330):1152-1158.
3. Zeman MK, Cimprich KA. Causes and consequences of replication stress. Nat Cell Biol. 2014 Jan;16(1):2-9.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
This article reviews how the intersection of HRD and replication stress provides a foundation for next-generation, functionally guided cancer treatments....
4 months ago
A comparative analysis shows that older age, elevated blood glucose, and abdominal adiposity are primary drivers of hypertension. Comprehensive evaluation of cardiometabolic risk profiles enables clinicians to detect overlapping metabolic dysfunctions early and optimize targeted prevention strategies.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Left ventricular thrombus is a severe complication of acute decompensated heart failure. This clinical review explores the pathophysiology, imaging challenges, and pharmacotherapeutic considerations of laminated thrombi, evaluating the evolving role of direct oral anticoagulants versus traditional warfarin.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
